1. Home
  2. TWST vs HAE Comparison

TWST vs HAE Comparison

Compare TWST & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TWST
  • HAE
  • Stock Information
  • Founded
  • TWST 2013
  • HAE 1971
  • Country
  • TWST United States
  • HAE United States
  • Employees
  • TWST N/A
  • HAE N/A
  • Industry
  • TWST Biotechnology: Biological Products (No Diagnostic Substances)
  • HAE Medical/Dental Instruments
  • Sector
  • TWST Health Care
  • HAE Health Care
  • Exchange
  • TWST Nasdaq
  • HAE Nasdaq
  • Market Cap
  • TWST 2.3B
  • HAE 2.3B
  • IPO Year
  • TWST 2018
  • HAE 1991
  • Fundamental
  • Price
  • TWST $31.42
  • HAE $48.89
  • Analyst Decision
  • TWST Buy
  • HAE Buy
  • Analyst Count
  • TWST 9
  • HAE 8
  • Target Price
  • TWST $48.56
  • HAE $76.88
  • AVG Volume (30 Days)
  • TWST 1.8M
  • HAE 1.1M
  • Earning Date
  • TWST 11-17-2025
  • HAE 11-06-2025
  • Dividend Yield
  • TWST N/A
  • HAE N/A
  • EPS Growth
  • TWST N/A
  • HAE 46.89
  • EPS
  • TWST N/A
  • HAE 3.28
  • Revenue
  • TWST $362,273,000.00
  • HAE $1,346,046,000.00
  • Revenue This Year
  • TWST $22.11
  • HAE N/A
  • Revenue Next Year
  • TWST $17.50
  • HAE $6.42
  • P/E Ratio
  • TWST N/A
  • HAE $15.11
  • Revenue Growth
  • TWST 22.72
  • HAE 0.91
  • 52 Week Low
  • TWST $24.07
  • HAE $47.32
  • 52 Week High
  • TWST $55.33
  • HAE $94.99
  • Technical
  • Relative Strength Index (RSI)
  • TWST 69.28
  • HAE 37.27
  • Support Level
  • TWST $26.20
  • HAE $47.56
  • Resistance Level
  • TWST $33.12
  • HAE $50.60
  • Average True Range (ATR)
  • TWST 1.49
  • HAE 1.38
  • MACD
  • TWST 0.68
  • HAE 0.47
  • Stochastic Oscillator
  • TWST 75.75
  • HAE 39.50

About TWST Twist Bioscience Corporation

Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to realize opportunities ahead rapidly. Geographically, it derives a majority of its revenue from the United States.

About HAE Haemonetics Corporation

Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.

Share on Social Networks: